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a b s t r a c t
Productive infection of human amniotic and endothelial cell lines with Japanese encephalitis virus (JEV)
was established leading to the induction of NFκB and HLA-F, a non-classical MHC molecule. Induction of
the HLA-F gene and protein in JEV-infected cells was shown to be NFκB dependent since it was blocked
by inhibitors of NFκB activation. ShRNA targeting lentivirus-mediated stable knockdown of the p65
subunit of NFκB inhibited JEV-mediated induction of HLA-F both in the amniotic cell line, AV-3 as well as
the human brain microendothelial cell line, HBMEC. The induction of HLA-F by treatment of AV-3 with
TNF-α was also inhibited by ShRNA mediated knockdown of NFκB. TNF-α treatment of HEK293T cells
that were transfected with reporter plasmids under the control of HLA-F enhancer A elements resulted
in signiﬁcant transactivation of the luciferase reporter gene. NFκB-mediated induction of HLA-F
following JEV infection and TNF-α exposure is being suggested for the ﬁrst time.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Japanese encephalitis virus (JEV) is a neurotropic virus that is
endemic in several parts of India and South East Asia (Halstead and
Jacobson, 2003; Misra and Kalita, 2010). It is a positive single
stranded RNA virus that belongs to the Flavivirus genus of the
family Flaviviridae (Lindenbach and Rice, 2003) and causes ence-
phalitis in newborn children and young adults. Its structural,
pathological, immunological and epidemiological aspects have been
well studied (Halstead and Jacobson, 2003; Heinz and Allison,
2000; Kurane, 2002). The ability of ﬂaviviruses to upregulate the
cell surface expression of MHC-I (Kurane, 2002; Shen et al., 1997)
has been shown to be dependent on IFN-β as well as NFκB.
We have also reported that JEV induces nonclassical MHC-I
molecules such as H-2Qa-1b (Abraham et al., 2008) and soluble
HLA-E (Shwetank et al., 2013) in addition to classical MHC-I
molecules. Among the known human non-classical antigens – HLA-
E, -F and -G, only the HLA-F gene has been reported to be regulated
by NFκB using in vitro gene reporter assays (Gobin and van den Elsen,
2000) and JEV is known to activate NFκB (Cheng et al., 2004). One
study reports an increase in HLA-F RNA expression in rabies virus
infected neuronal cells (Megret et al., 2007) but there are no other
reports of virus mediated alterations in HLA-F gene expression.
Hence it was of interest to study if JEV infection would activate
NFκB in human cells leading to functional HLA-F gene induction.
We examined the effect of JEV infection on the expression of the
HLA-F gene in AV-3 and WISH cells since they have been used as
model cell lines to study intrauterine infection and amniotic inﬂam-
matory responses (Pavan et al., 2003; Potter et al., 1999). Amniotic
epithelial cells and mid-trimester placental tissues are known to
express the nonclassical MHC molecules, HLA-F and HLA-G (Adinolﬁ
et al., 1982; Shobu et al., 2006). In addition, the bladder carcinoma-
derived epithelial cell line, ECV 304 (ECV) and immortalized human
brain microvascular endothelial cells (HBMECs) were also included in
the study since they have been used as models of the blood brain
barrier (Untucht et al., 2011; Wilhelm et al., 2011). We show here
that JEV establishes productive infection in all these cell lines and
leads to induction of HLA-F at the gene and protein levels. This HLA-F
induction was partially dependent on the activation of NFκB in JEV-
infected cells as shown by inhibitor and p65 knockdown experi-
ments. More importantly, HLA-F was shown to be inducible by TNF-
α, a cytokine that is known to be induced during JEV infections (Ravi
et al., 1997).
Results
JEV infection and induction of HLA-F
Productive JEV infection of several different mouse cell types
including mouse embryonic ﬁbroblasts as well as its ability to induce
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classical and nonclassical MHC molecules has been reported earlier
(Abraham et al., 2010; Lobigs et al., 2003). Hence we tested the
effects of JEV infection on the expression of the human nonclassical
molecule, HLA-F in different human cell types. The human amnion-
derived cell types, AV-3 and WISH were infectable as seen by the
presence of the JEV nonstructural protein, NS3 (Fig. 1A and B) as well
as the intracellular presence of HB112, a ﬂavivirus group speciﬁc
antigen at 12 h and 24 h post-infection (Fig. S1) and PFU release
(1–2105/ml at 30 h p.i.). Similarly, both ECV and HBMECs were
infected with JEV (Fig. 1C and D) conﬁrming our previous study
(Shwetank et al., 2013). As shown in Fig. 1, transcription of the HLA-F
gene was progressively induced by JEV in all cell types in a time-
dependent manner and was followed by a concomitant increase in
intracellular HLA-F antigen as measured by 3D11 monoclonal reac-
tivity (Fig. 1, right panel). The position of the 3D11 immunoreactive
band was authenticated as HLA-F by the detection of a 42 kDa band
in cell lysates of a HLA-F negative cell line BeWo that expressed the
antigen only after transfection with HLA-F pcDNA 3.1 (Fig. S2C). The
band marked by the arrow corresponded to the predicted HLA-F
molecular weight of 42 kDa approximately (Wainwright et al., 2000).
Increased HLA-F gene transcription was not observed when AV-3
and WISH cells were infected for 36 h with UV inactivated virus
suggesting that virus replication was needed (Fig. 1A and B). Similar
results were observed with ECV and HBMEC cells using UV inacti-
vated virus (data not shown). These data were further conﬁrmed by
real time PCR analysis as shown in Table 1. Induction of the HLA-F
gene increased from 12 h p.i., and reached maximum levels between
24 h and 36 h of infection (Table 1) in the above cell lines.
NFκB activation in JEV infected human amniotic and endothelial cell
lines
A major role for NFκB in MHC induction was not evident in our
previous studies using JEV-infected mouse embryonic ﬁbroblasts
(Abraham et al., 2010). However, ﬂaviviruses such as West Nile
Virus induce MHC antigen expression through NFκB dependent and
independent pathways (Cheng et al., 2004). Binding of NFκB to the
κB1 site present in the enhancer A module of the HLA-F promoter
has been demonstrated (Gobin et al., 1998). Hence we ﬁrst tested if
JEV was able to activate NFκB in human amniotic and endothelial
cells. As shown, JEV infection of AV-3, WISH, ECV and HBMEC cells
led to a time-dependent (Fig. 2A and B) and virus dose-dependent
(Fig. S4) binding of NFκB to the κB1 oligomer. The position of the
NFκB-oligo complex in JEV-infected cell extracts was veriﬁed by
treatment of AV-3 cells with okadaic acid that is known to activate
NFκB (Fig. 2, Pos). In addition, the supershifted band observed upon
addition of anti-p65 NFκB antibody conﬁrmed that the complex
was NFκB1 speciﬁc (Fig. 2B) in all cell lines tested. The complex was
not formed when the κB2 oligo was used in EMSA (Fig. 2B)
conﬁrming the earlier report that the HLA-F κB2 site does not bind
NFκB (Gobin et al., 1998). Cells were then infected with JEV in the
Fig. 1. HLA-F induction in JEV infected cells. As shown at the top, whole cell lysates
(35 μg protein) from AV-3, WISH (Panel A and B), ECV and HBMEC (Panel C and D)
cells were subjected to Western blotting using rabbit anti JEV-NS3 (JEV-NS3
Protein) or 3D11 anti HLA-F moAb (HLA-F Protein). Total RNA extracted from the
cells was subjected to semiquantitative RT-PCR analysis (HLA-F gene) for HLA-F
gene expression. In each panel, the top row represents the results obtained for
Western blotting and RT-PCR analysis while the bottom row represents controls for
β-tubulin protein and β-actin gene expression. JEV infection was done for 12, 24 and
36 h while ‘UV’ in panels A and B represents infection of AV-3 and WISH for 48 h
with UV inactivated JEV. Numbers indicated at the bottom of each panel represents
the fold change over control (Con) after normalization for β-tubulin protein or β-
actin gene expression.
Table 1
Real Time PCR analysis of HLA-F gene transcription.
Time of infection Cell linea
AV-3 WISHb ECV HBMEC
Control 1.070.10 1.070.18 1.070.14 1.070.07
12 h 3.270.05# 1.570.13 2.170.23 2.770.01#
24 h 10.670.23n 12.170.03n 17.370.53n 15.770.24n
36 h 13.070.20n 12.270.03n 14.470.11n n.dc
a Data represent fold change over control.
b Wish cells infected for 36 h with UV inactivated virus gave a value of 1.570.2.
c Not determined.
n Po0.001.
# Po0.01.
Fig. 2. NFκB activation in JEV infected human cell lines. EMSA was performed with
NF-κB1 oligomer using nuclear extracts from AV3, WISH, ECV and HBMEC cells as
indicated either alone (Panel A) or in the presence of either anti-p65 antibody
(Panel B) or NFκB inhibitor, Bay 11-7085 (Panel C). Panel A: Lanes U and Pos
represent uninfected cells and cells treated with the positive control, okadaic acid
while lanes 1–3 represent cells that were JEV infected for 12, 18 and 24 h
respectively. Panel B: Lane U represents uninfected cells while lane ‘Neg’ represents
EMSA results obtained with JEV infected cells and the NF-κB2 oligomer as a
negative control. Uninfected cells (Lane U) or 24 h JEV-infected cells were
incubated with the functional NF-κB1 oligomer, either alone (Lane 1) or in the
presence of anti-p65 (Lane 2) and 15 fold excess anti-p65 antibody (Lane 3 for ECV
only). Panel C: Lanes marked Neg1 and Neg2 indicate EMSA results obtained using
the NF-κB2 oligomer for 24 h JEV-infected and normal uninfected cells respectively.
Lanes 1–3 show 24 h JEV-infected cells that were either untreated (Lane 1) or
treated with 10 mM (Lane 2) and 15 mM (lane 3) Bay. The protein–oligomer complex
and the antibody-supershifted complex are indicated by arrows.
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presence of the NFκB inhibitor, Bay 11-7085 in order to check if the
JEV-induced NFκB activation was inhibited in the human cell lines
tested. Treatment of both WISH and AV-3 cells with Bay 11-7085
during virus infection clearly inhibited JEV-induced NFκB activation
as seen in Fig. 2C. Similar results were obtained with ECV and
HBMECs (Fig. 2C).
Stable knockdown of p65 NFκB abrogates HLA-F induction
NFκB is a heterodimeric DNA-binding protein complex consist-
ing of p50/p65 subunits. NFκB activation is regulated by diverse
stimuli in different cell types and mediates different functions
(Perkins and Gilmore, 2006) that are believed to bridge inﬂamma-
tion and cancer. Hence virus-infected cells were treated with the
NFκB inhibitor, Bay 11-7085 to check its effect on HLA-F expression.
Intracellular expression of HLA-F antigen was found to decrease in
all cell lines upon treatment with Bay as shown in Fig. 3A and B.
HLA-F gene induction was also measured by real-time RT-PCR
quantiﬁcation in the infected cells treated with Bay 11-7085. Results
obtained showed that HLA-F gene induction was also inhibited
signiﬁcantly by treating the cells with Bay 11-7085 (data not
shown). Viral synthesis of JEV-NS3 non-structural protein remained
unaffected by Bay (Fig. S3) treatment suggesting that NFκB might
play a role in JEV mediated induction of HLA-F.
RNA interference using lentiviral vectors coding for shRNA that
downregulate p65 expression has been used to block NFκB signaling
pathway in order to analyze its role in the function of VEGF and
many other growth factors in tumor metastasis (Huang et al., 2000).
In order to further conﬁrm the role of NFκB, stable mutant HBMEC
and AV-3 cell lines were generated by transduction and selection
using lentiviral vectors expressing shRNA constructs that targeted
three different p65 microRNA sequences called Shrna1, Shrna2 and
Shrna3 as given in Material and methods. Nontargeting lentivirus
particles served as controls. Western analyses revealed that the
decrease in p65 expression was maximal in mutant HBMEC and AV-
3 cells that were transduced with Shrna1 lentiviral particles
(Fig. 4A). Hence further analyses with JEV infection were done with
Shrna1 mutant cells (Fig. 4B). Virus infection was conﬁrmed by
detection of the JEV-NS3 nonstructural protein in all cell lines by
Western blotting. The JEV induction of HLA-F was signiﬁcantly
decreased upon p65 knockdown with Shrna1 as seen in Fig. 4B.
Additionally, control Shrna and Shrna1 cells were treated with
TNF-α as a positive control (Bouwmeester et al., 2004). Also, JEV
infection activates production of pro-inﬂammatory cytokines such as
TNF-α, IL-8, RANTES, IL-1 and IFNs (Chen et al., 2011; Ghosh and
Basu, 2009) in different cell types. As shown in Fig. 4B, treatment
with TNF-α increased the expression of 3D11 reactive HLA-F antigen
and this increase was also inhibited in Shrna1 expressing cells both
in HBMEC and AV-3. A separate experiment with AV-3 conﬁrmed
the decreased expression of p65 NFκB in shRNA mediated p65
knockout cells as seen in Fig. S5 showing clearly that NFκB played a
role in HLA-F expression.
TNF-α induces HLA-F gene expression
Since TNF-α treatment resulted in increased expression of HLA-F
antigen, it was of interest to check the effect of TNF-α treatment on
HLA-F gene expression. It was observed that HLA-F gene expression
was signiﬁcantly induced when AV-3 and HBMEC cells were treated
with 300 IU TNF-α for 24 h (Table 2). In addition, the TNF-α induced
HLA-F gene expression could be inhibited by two inhibitors of NFκB
activation pointing to its possible involvement in HLA-F gene
induction. Similar inhibitory effects were also observed when the
NFκB inhibitory peptide was tested on JEV infected cells but the
results obtained with the control and inhibitory peptides were
extremely variable (data not shown). This could possibly be due to
the extensive induction of membranes by JEV that are essential for
viral replication (Salonen et al., 2005; Uchil and Satchidanandam,
2003) but could interfere with the intracellular membrane transdu-
cing efﬁciency of the PTD in control and inhibitory peptides. Hence
the results described thus far encouraged us to test the effect of JEV
infection and TNF-α treatment on HLA-F gene expression in AV-3
cells that were stably knocked down for NFκB as described above.
HLA-F gene expression increased in a time dependent manner in
both instances of JEV infection as well as TNF-α treatment and the
increase obtained at 24 h of treatment signiﬁcantly decreased in
Fig. 3. Effect of NFκB inhibition on HLA-F expression in JEV infected cells. As
labeled, whole cell lysates (35 mg) of uninfected and 24 h JEV infected HBMEC, AV-3
(Panel A), ECV and WISH (Panel B) cells were either left untreated (Con) or treated
with Bay 11-7085 (Bay) for 24 h and subjected to Western blotting using anti HLA-F
(Top row) and anti β-tubulin (Bottom row) antibodies.
Fig. 4. Effect of NFκB knockdown on HLA-F antigen expression in JEV infected cells.
Panel A: HBMEC and AV-3 cells were transduced either with control non-targeting
lentivirus (cShrna) or with three different lentivirus particle clones (Shrna1, Shrna2
and Shrna3) each targeting different microRNA sequences of RELA as given in
Materials and methods. Sorted cells stably expressing the Shrna were lysed and the
lysate protein (35 mg) was subjected to Western blotting using anti NF-κBp65 (Top)
and anti β-tubulin (Bottom) antibodies. Panel B: As labeled at the bottom, HBMEC
and AV-3 cells that were transduced with control non-targeting lentivirus (cShrna)
or Shrna1 targeting lentivirus particle clone were left untreated (Con), infected
with JEV for 24 h (Jev) or treated with TNF-α for 24 h (Tnfα). Cell lysates (35 mg
protein) were subjected to Western blotting using anti HLA-F (Top), anti β-tubulin
(Middle) anti JEV-NS3 (Bottom) antibodies. Numbers (Fold) indicate the fold
change over control (Con) obtained after normalization for β-tubulin protein.
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Shrna1 knockdown cells pointing to an involvement of NFκB in its
induction (Fig. 5).
Locus-speciﬁc variation in the binding of NFκB and other
transcriptional factors to the κB1 and κB2 sites present in the
enhancer A region of the HLA-F gene controls its expression (Gobin
et al., 1998). Differential binding of the enhancer A elements by
transcriptional factors and transactivation regulates MHC Class I
gene expression in different cell types following cytokine exposure
(Gobin and van den Elsen, 2000). Hence we checked if these two
sites of the HLA-F enhancer A would mediate transactivation
following TNF-α mediated NFκB activation. HEK293T cells were
transfected with luciferase reporter plasmids driven by the enhan-
cer A elements of HLA-F or HLA-A as given inMaterials and methods.
Luciferase activity was measured after treatment with TNF-α, IL-1β
and IFNβ. As shown in Fig. 6 (Expt 1, top panel), TNF-α treatment of
these transiently transfected HEK293T cells signiﬁcantly increased
the luciferase activity in a time dependent manner relative to the
control plasmid. Similarly, IL-1β and IFNβ also resulted in increased
luciferase activity after treatment for 3 h (Fig. 6, Expt 2, bottom
panel). Enhancer A of HLA-A (enh A) served as the positive control
since it has been shown that it would transactivate luciferase
expression in Tera cells when co-transfected with p50 and p65
plasmid constructs (Gobin et al., 1998).
Cell surface expression of HLA-F on JEV infected cells
Cell surface expression of HLA-F has not been observed alt-
hough present intracellularly in a number of cell lines (Lepin et al.,
2000; Wainwright et al., 2000). It has so far been reported to be
expressed only on the cell surface of placental trophoblast cells
(Ishitani et al., 2006), EBV transformed lymphoblastoid cells and
some monocytic cell lines (Lee and Geraghty, 2003) as well as
activated T lymphocytes (Goodridge et al., 2010; Lee et al., 2010).
Hence it was of interest to check if JEV infection could upregulate
cell surface HLA-F expression. As shown in Fig. 7, cell surface
expression of HLA-F antigen increased only on HBMEC from 2.8%
in uninfected cells to 18.4% in infected cells at 36 h after infection.
No change was observed on AV-3 cells. Cell surface expression of
total HLA (-A, -B and -C) antigens was also analyzed using the pan
HLA-speciﬁc W6/32 antibody. Both cell types constitutively
expressed total HLA on the surface which did not increase upon
JEV infection conﬁrming our earlier report (Shwetank et al., 2013).
Discussion
HLA-F and HLA-G is expressed on mid-trimester placental cells
and extravillous trophoblasts (Ishitani et al., 2006). Little is known
regarding the role of HLA-F in these tissues. We have examined the
status of HLA-F gene expression in human amniotic and endothe-
lial cell lines since these cells are components of barrier systems
(Kobayashi et al., 2010; Stamatovic et al., 2008). JEV has been
shown to cross these barriers as shown by the occurrence of
human transplacental infection by JEV (Chaturvedi et al., 1980).
Intrauterine infection by JEV (Mathur et al., 1982) and West Nile
virus has also been reported (Julander et al., 2006). Also, the
effects of JEV infection on embryonic cell types per se have not
been studied in detail. After our initial studies with AV-3, WISH,
ECV and HBMECs, p65NFκB knockdown was performed with AV-3
and HBMECs due to the relatively better stability obtained in their
TurboGFP expression following lentiviral infection.
JEV was able to establish productive infection in AV-3 and WISH
as well as ECV and HBMECs as judged by the expression of the NS3
non-structural protein and the ﬂaviviral group speciﬁc antigen
(Fig. 1 and S1) as well as release of fresh viral PFU. EMSA studies
also showed that JEV infection activated NFκB in all the cell lines
tested. Interestingly, only the κB1 oligo complex was observed with
the nuclear extracts of infected cells. The κB2 oligo failed to show
Table 2
Effect of TNF-α on HLA-F induction.
Treatment Cell linea
AV-3 HBMEC
TNF-α 6.0670.05 7.1670.16
Plus Bay 15 mM 2.3070.17n 2.8370.20n
TNF-α 8.1171.12 6.6372.29
Plus inhibitory peptideb 5.4470.41n 1.5770.02n
a Data represent fold change over control untreated cells.
b Fold change observed upon incubation of TNF-α treated AV-3 cells with
control peptide was 7.5870.42.
n Po0.001.
Fig. 5. Effect of NFκB inhibition on HLA-F gene expression. AV-3 cells that were
transduced with control non-targeting lentivirus (cShrna) or Shrna1 targeting
lentivirus particle clone were infected with JEV (JEV) at MOI 1 or treated with
500 U/ml TNF-α (TNF) for different periods of time as indicated. Cells were
harvested and used for extraction of RNA and analysis of HLA-F gene expression
by real time quantiﬁcation. cShrna and Shrna1 transduced cells that were mock
treated for 24 h were taken as controls and data were calculated as fold change
over control Shrna RNA7SD of triplicates. Mock treated Shrna1 controls did not
differ signiﬁcantly from cShrna controls. Data represent mean fold change over
control RNA7SD (**Po0.001).
Fig. 6. TNF-α induces HLA-A and HLA-F. HEK293T cells were transiently transfected
with luciferase reporter plasmid constructs containing the control construct pGL3-
basic alone or constructs containing enhancer A region of HLA-F (enhF) or enhancer
A region of HLA-A (enhA) linked to pGL3-A140. The cells were treated with TNF-α
(500 U/ml) for 2, 3 and 9 h in the upper panel (Expt 1) while they were treated with
TNF-α (500 U/ml), IL-β (1 ng/ml) or IFNβ (500 U/ml) for 2 h in the lower panel (Expt
2). The luciferase activity values were normalized with β-galactosidase activity and
are expressed as mean7SD of n¼3.
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activation by EMSA studies in infected cells (Fig. 2). However, both
the HLA-F gene and the protein were induced following JEV
infection reﬂecting the possibility that the ﬂanking sequences of
the enhancer A region were helping in transactivation of the HLA-F
gene as reported earlier (Gobin and van den Elsen, 2000). This
conclusion is supported by our ﬁnding that Shrna1 knockdown
failed to completely inhibit the expression of the HLA-F gene (Fig. 5)
and intracellular protein in AV-3 cells (Fig. 4). Similarly, the effect of
the NFκB inhibitor, Bay was incomplete in these cells suggesting
that other pathways and cytokine factors could be controlling HLA-
F expression in infected cells. A separate binding site for IRF-1, for
example has been shown to be involved in HLA-gene induction by
IFN-γ (Gobin et al., 1999).
Our study is the ﬁrst to report that JEV induced NFκB activation can
actually lead to HLA-F gene induction, not only in amniotic cells but
also in endothelial cells. This effect is possibly mediated via TNF-α
secretion since this cytokine has been shown to increase in JEV
infections (Chen et al., 2011; Ravi et al., 1997). Although lower than
JEV-infected cells, TNF-α induced HLA-F gene expression was also
inhibited albeit partially by two NFκB inhibitors (Table 2) as well as by
Shrna1 knockdown experiments (Fig. 5). Taken together, these experi-
ments clearly support the involvement of NFκB in HLA-F induction.
Our plasmid reporter assays showed that TNF-α treatment of
transfected HEK293T cells was also able to transactivate the
luciferase gene that was placed under the control of the enhancer
A elements of the HLA-F gene (Fig. 6). The κB1 site in enh F of the
pGL3-basic construct does not successfully transactivate the HLA-F
gene although bound by NFκB (Gobin and van den Elsen, 2000).
These studies were done in Tera cells that were cotransfected with
p50 and p65 plasmid constructs along with enh F containing
luciferase reporter plasmids. However, we observed that enh F was
functional in our reporter assays using HEK293T cells that were
treated with different cytokines and all these assays were vali-
dated using the enh A pGL3-basic construct. The reason for this
observation is yet unclear but it is possible that additional
cytokine-induced transcriptional factors may bind κB1 and/or
ﬂanking sequences of enh A in HEK293T cells that would help in
the transactivation. This possibility is supported by our observa-
tion that in addition to TNF-α, two other cytokines - IL-β and IFN-β
also were also functional in transactivating the luciferase reporter
gene. Both these cytokine genes are induced in infected cells
(Shwetank et al., 2013 and data not shown).
The increase in cell surface expression of HLA-F was modest and
was observed only on a fraction of HBMEC cells (Fig. 7) although JEV
induced HLA-F gene expression in AV-3 and HBMEC cells (Table 1).
Similarly, TNF-α treatment did not result in upregulation of cell
surface HLA-F expression (data not shown) although the gene was
induced in AV-3 and HBMEC cells (Table 2). Signiﬁcant changes in
HLA-F cell surface expression were also not observed on ECV cells
(data not shown). The reason for this anomaly is unclear at this time
but it must be mentioned that cell surface expression of HLA-F has
not been observed although present intracellularly in a number of
cell lines (Lepin et al., 2000; Wainwright et al., 2000). It has so far
been reported to be expressed only on the cell surface of placental
trophoblast cells (Ishitani et al., 2006), EBV transformed lympho-
blastoid cells and some monocytic cell lines (Lee and Geraghty,
2003) as well as activated T lymphocytes (Goodridge et al., 2010;
Lee et al., 2010).
HLA-F tetramers have been reported to bind to inhibitory NK
receptors in vitro suggesting a possible role for cell surface HLA-F
induction in immune evasion (Goodridge et al., 2013). However, the
signiﬁcance of intracellular increase of HLA-F that was observed
upon JEV infection in amniotic cells is still unclear. It is possible that
these molecules could play a similar immune-evasive role upon
release from infected cells either as a consequence of apoptosis or
shedding. JEV has also been shown to cause metalloproteinase
dependent shedding of sHLA-E that has the ability to inhibit IL-2
induced ERK phosphorylation and proliferation in NK cell lines
(Shwetank et al., 2014). Based on a detailed study on the contribution
of its cytoplasmic tail in ER to golgi transport, a unique alternative
Fig. 7. JEV infection and cell surface expression of HLA antigens. As labeled, AV-3 and HBMEC were stained for the cell surface expression of HLA-F at 12 (Panels A, E), 24
(Panels B, F), and 36 h (Panels C, G), and total HLA class I (Panels D, H) at 36 h after JEV infection. Filled histograms represent cells alone, solid lines represent staining with
control secondary (Panels A, B, C, E, F, G) or isotype (Panels D, H) antibody while dotted lines marked by arrows represent antigen-speciﬁc staining. Insets represent staining
of uninfected cells. Numbers represent the percent antigen-speciﬁc positive cells (dotted lines) obtained in the marked M1 marker region after substracting the percent
positive cells for control/isotype antibody (solid lines).
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function for intracellular HLA-F in monitoring the golgi for infections
has also been proposed (Boyle et al., 2006). Further studies will help
in substantiating these hypotheses in JEV infected cells. The expres-
sion of HLA-F has also been associated with poor survival in cancer
patients (Zhang et al., 2013). Hence we believe that the increase in
cell surface expression of HLA-F on JEV infected HBMEC as well as
the intracellular HLA-F induction in amniotic cells could be signiﬁ-
cant. Overall, our observations about the induction of HLA-F by JEV
and its regulation by TNF-α and NFκB activation suggest a possible
role in viral disease.
Conclusions
Both human amniotic and endothelial cells were infected by JEV
leading to induction of the gene expression of the nonclassical MHC
molecule HLA-F. Cell surface expression was induced only on
human brain microvascular endothelial cells and not all cell types
tested. Induction of HLA-F gene expression by JEV was dependent,
at least partially on NFκB and could also be brought about by TNF-α
treatment.
Materials and methods
Media, antibodies, and cell lines
Trizol, Bradford reagent, Coomassie Brilliant Blue stain, leupep-
tin, PMSF, Dulbecco's modiﬁed Eagle's medium (DMEM), sodium
pyruvate and MEM vitamin solution were purchased from Sigma-
Aldrich, India. FCS was obtained from Gibco, USA and Nu-Serum
from BD Biosciences, USA. Revert Aid Moloney murine leukemia
virus (M-MuLV) reverse transcriptase and Taq polymerase were
obtained from MBI Fermentas, Lithuania while iQ SYBR Green
Supermix 2 was purchased from Bio-Rad, USA. Anti HLA-F mouse
monoclonal antibody, 3D11 for Western blotting and cell surface
staining was a kind gift from Dr. Geraghty, Fred Hutchinson Cancer
Research Center, Seattle, USA. Goat anti-mouse IgG (Fcγ chain-
speciﬁc) secondary antibody conjugated to FITC was from Jackson
Immunoresearch Labs, USA and goat anti rabbit IgG (HþL) con-
jugated to Alexa Fluor 488 was obtained from Invitrogen, USA. The
Flavivirus mouse monoclonal antibody, HB112 was used either as
culture supernatants or puriﬁed antibody. Anti-p65 NFκB rabbit
monoclonal antibody was obtained from Cell Signaling Technology,
USA. Rabbit anti β-tubulin IgG for Western blotting was obtained
from Imgenex, India. Goat anti rabbit IgG-HRP conjugate was from
Bangalore Genei, India. Puriﬁed human TNF-α was obtained from
Peprotech, Israel
The human amniotic epithelial cell line, AV-3 was obtained from
NCCS, Pune while WISH was a gift from Dr. Ajit Kumar, Indian
Institute of Science and BeWo, a HLA-F negative cell line was
obtained from Dr A.J. Rao, Indian Institute of Science. They were
grown in DMEM containing 10% FCS. Human Brain Microvascular
Endothelial cells (HBMEC) transfected with a plasmid containing
the SV40 Large T antigen were cultured in DMEM containing 10%
FCS, 10% Nu-Serum, glutamine, non-essential aminoacids, sodium
pyruvate and MEM vitamin solution (Stins et al., 2001; Takahashi et
al., 1990). ECV304 (ECV) cell line was a kind gift from Dr. M. Jaggi,
Dabar Research Center, Ghaziabad, India. ECV is a human bladder
carcinoma-derived epithelial cell line that is used as an endothelial
cell model (Brown et al., 2000; Wilhelm et al., 2011). ECV cells were
cultured in DMEM containing 10% FCS. PS (porcine kidney) cells
were grown in minimum essential medium (MEM) supplemented
with 10% FCS and used for virus titrations, while C6/36 mosquito
cells were grown in MEM supplemented with 10% FCS and 10%
tryptose phosphate broth and used for virus collection. HEK293T
cells were grown in 10% DMEM.
Virus and infection of cells
JEV strain P20778, was propagated on a conﬂuent layer of C6/36
cells that were grown to conﬂuency at 28 1C. Culture supernatants
from C6/36 cells infected with JEV were collected after every 8 h,
from 24 to 80 h and stored at 70 1C until they were used for
infection of cell lines. Virus titers were evaluated by plaque forming
unit (PFU) assays on porcine kidney (PS) cells (Abraham et al., 2010).
Cells were infected with virus at MOI of 10 in DMEM containing
1.5% FCS. After 2 h of infection, cells were washed once with
incomplete medium and replenished with DMEM containing 2.5%
FCS. Thereafter, cells were harvested at different times post-
infection (p.i.) and used for RNA extraction, Western blotting,
nuclear extract preparation and ﬂow cytometric (FACS) analysis.
Control cells were similarly mock infected with uninfected C6/36
cell culture supernatant.
For NFκB inhibitor experiments, JEV-infected cells (7.5105)
were cultured in the presence of 10 μm and 15 μm of Bay 11-7085
(Sigma, India) for the times mentioned. All cells were pretreated
with the inhibitor for 1 h before JEV infection. DMSO solvent
controls were also included which did not differ signiﬁcantly from
untreated controls. In the case of TNF-α treatment, AV-3 and
HBMEC cells were treated with a peptide inhibitor of NF-κBp65
(Ser276) (DRQIKIWFQNRRMKWKKQLRRPSDRELSE, Imgenex, USA)
for 24 h along with 300 IU of TNF-α (Takada et al., 2004). Controls
included the addition of control peptide with only the protein
transducing domain (DRQIKIWFQNRRMKWKKQ) along with
TNF-α.
Plasmids
SMARTvector 2.0 hCMV-turboGFP Lentiviral Human RELA
shRNA particles were obtained from Thermo Fisher Scientiﬁc,
USA. The three individual microRNA sequences targeted were
ATCAGTCAGCGCATCCAGA, GGATTGAGGAGAAACGTAA and GCTA-
TAACTCGCCTAGTGA. SMARTvector 2.0 Non-targeting hCMV-tur-
boGFP Lentiviral particles were used as controls.
Enhancer A-containing HLA-F (enh F) and HLA-A (enh A)
plasmid reporter constructs that were cloned upstream of the
ﬁreﬂy luciferase gene in pGL3-Basic (a kind gift from Dr. Peter J
van den Elsen) were used in transient transfection assays. These
contained both κB1 and κB2 motifs of the enhancer A sequence of
either HLA-F or HLA-A genes and were cloned upstream of a 143-
bp HLA-An0201 promoter fragment in pGL3-A140 (Gobin et al.,
1999).
For the purpose of transfecting HLA-F negative BeWo cells, the
HLA-F gene was ampliﬁed from HLA-F-pCMV6 sport vector (Open
Biosystem, USA) with the Forward primer 50-CGCGGATCCGCCAC-
CATGGCGCCCCGAAGCCTC-30 and reverse primer 50-GCTCCGGAATTCT-
CACACTGCAGCCTGAGAGTAGCTC-30 carrying BamHI and EcoRI
Restriction sites using Q5 High-ﬁdelity DNA polymerase (NEB, USA).
The PCR product was digested with BamHI and EcoRI and cloned in
pcDNA 3.1 to generate HLA-F pcDNA 3.1 which was used for
transfection.
Semiquantitative reverse transcriptase (RT PCR) analysis
Total RNAwas isolated from control and infected cells at different
times p.i., using Trizol (Sigma-Aldrich, India) reagent according to
the manufacturer0s instructions. First strand cDNA was made from
2 μg of RNA using oligo dT primers and Revert Aid™ M-MuLV
Reverse Transcriptase from MBI Fermentas, Canada. PCR was per-
formed with different dilutions of cDNA using Taq-DNA polymerase
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and gene-speciﬁc primers in a total reaction volume of 50 μl using a
Peltier thermal cycler from Bio-Rad, USA. PCR was performed for 35
cycles in the case of HLA-F and 23 cycles for β-actin. PCR cycles
comprised of 95 1C for 4 min, 94 1C for 1 min, 60 1C for 1 min, 72 1C
for 1 min and ﬁnal extension at 72 1C for 10 min. Ampliﬁed PCR
products were separated by agarose (2%) gel electrophoresis.
The gene speciﬁc primers used for semi-quantitative PCR
were HLA-F, 50-TATTGGGAGTGGACCACAGGGTAC-30 and 50-GGCA-
CAAGTGCAATTCTGCTAC-30; β-Actin, 50-ATCTGGCACCACACCTTC-
TACAATGAGCTGCG-30 and 5-CGTCATACTCCTGCTTGCTGATCCA-
CATCTGC-30. Several standardization experiments were performed
to ensure the semiquantitative nature of the results obtained.
Quantititative real time PCR analysis
The real-time PCR for the relative quantiﬁcation of genes was
performed using a Bio-Rad iQ5 system (Bio-Rad, USA) and cDNA
prepared from 2 mg of Trizol extracted RNA using random primers
or oligo dT primers. Real-time PCR mixtures contained 10 ml of 2
iQ SYBR Green Supermix (Bio-Rad, USA), 0.75 ml of each primer
(10 mM), 5 ml of 1:50 diluted cDNA and water in a ﬁnal volume of
20 ml. The thermal cycling conditions were: 50 1C for 2 min and
95 1C for 2 min, followed by 45 cycles of 95 1C for 15 s and 60 1C
for 1 min. The ﬁnal stage consisted of 95 1C, 60 1C and 95 1C for
15 s each to check the melting curve for the formed amplicons and
the speciﬁcity of the primers. ΔCt values for all genes were
obtained using the Bio-Rad iQ5 Software from which relative fold
change was determined using the threshold cycle (2ΔΔCt)
method where β-actin was used as a reference gene for normal-
ization of theΔCt values of target genes. The gene-speciﬁc primers
used were: HLA-F, 50-ATCGTTGCTGGCCTTGTTGTCCTT-30 and 50-
GGCACAAGTGGAATTCTGCTAC-30; β-actin, 50-CAAGATCATTG-
CTCCTCCTG-30 and 50-AGGGTGTAACGCAACTAAGTCAT-30. Data
was analyzed by one-way ANOVA with Dunnett's post-test using
GraphPad Version 5.00 and represented as mean fold change7SD
of three independent PCR analyses.
EMSA
3106 cells were harvested, washed twice with PBS and the cell
pellet was resuspended in ice cold Buffer A (10 mM HEPES pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF)
by gentle pipetting. The cells were allowed to swell on ice for
30 min, after which 10% solution of NP-40 was added and the tube
was vigorously vortexed. The solubilised suspension was centrifuged
at 4 1C for 2 min at 12,000 rpm in a microfuge and the nuclear pellet
was resuspended in ice-cold buffer B (20 mM HEPES pH 7.9, 0.4 M
NaCl, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF)
containing 10 μg/ml leupeptin and aprotinin. The tubes were
vigorously rocked at 4 1C for 30 min on a rocker. The nuclear extracts
were centrifuged and the supernatant containing nuclear proteins
were stored at 70 1C until analysis by Bradford assay and EMSA.
Double-stranded oligonucleotides containing the HLA-F promoter
NF-κB1 consensus (50-GTTGAGAATTCCCCCTGCA-30) and NF-kB2 (50-
GGTTGGAAGGCTCACTGCA-30) primer sequence (Gobin et al., 1998)
were used. The oligonucleotides were end-labeled with [γ-32P] ATP
using T4 polynucleotide kinase (MBI fermentas, Lithuania). EMSA
was performed in a total volume of 20 μl at 4 1C. Nuclear extracts
(35 μg) were equilibrated for 20 min in binding buffer (10 mM Tris–
HCl, pH 8.0, 75 mM KCl, 2.5 mM MgCl2, 0.1 mM EDTA, 10% glycerol,
0.25 mM DTT) and 1 μg of poly-dI-dC (Sigma, India). The mixture
was incubated with 32P-labeled oligonucleotide probe for 30 min on
ice. Protein–DNA complexes were separated by electrophoresis on
5% native polyacrylamide gels followed by autoradiography for
visualization in a BioImage Analyzer (FLA5100, Fuji Film, and Japan).
For supershift assays, anti p65 NFκB antibody was added to nuclear
extracts and incubated for 30 min on ice before EMSA. Cells (1106)
were treated with 10 μM okadaic acid for 24 h as a positive control
for NFκB activation. Inhibition of NFκB activation was done by
treatment of cells (1106) for 24 h with 10 μM Bay 11-7085, a
reagent that inhibits IκB phosphorylation. Positive controls were
performed separately to conﬁrm the action of the inhibitors used
(data not shown).
Stable knockdown of p65 NFκB
Stable knockdown of p65 NF-kB was performed using a set of
three individual Human SMARTvector 2.0 hCMV-turboGFP Lenti-
viral Human RELA shRNA particles, each having an individual
shRNA design targeting RELA. These particles expressed turbo-GFP
and shRNA as part of a bicistronic transcript. The presence of a
puromycin drug resistance marker allowed the selection of stable
mammalian cell lines after transduction. Lentivirus transduction
was done using incomplete DMEM containing polybrene at 10 mg/
ml. Brieﬂy, AV-3 and HBMC cells were separately transduced with
three different lentivirus particle clones each targeting different
microRNA targeting sequences of RELA at MOI of 1 in a 48 well
format according to the manufacturer's instructions. After 72 h of
transduction cells were observed by ﬂuoresence microscopy for
turbo-GFP expression and antibiotic selection was performed
using puromycin at 3 mg/ml. Cells stably expressing Turbo-GFP
were sorted using MoFlow™XDP Beckman Coulter machine before
use in knockdown experiments. Nontargeting lentivirus particles
supplied by the company were used as controls.
Transient transfection
Transfection was done with 80% conﬂuent HEK293T cells in a 12
well format using Lipofectamine 2000 (Invitrogen, USA) according to
manufacturer's instructions. Brieﬂy, DNA and lipofectamine complex
were made in Opti-MEM and added drop wise on cells. DNA-lipid
complexes were removed after 6 h and complete medium was
added. A total of 1.5 mg DNA mix was used for transfection and
contained 600 ng each of HLA-F / HLA-A enhancer A luciferase
reporter plasmid, 600 ng of plasmids encoding various JEV non-
structural proteins and 300 ng pCMV-beta-gal plasmid. After 24 h of
transfection, cells were lysed in reporter lysis buffer according to the
manufacturer's instructions (Promega, USA). 10 mg of lysate was used
to measure luciferase activity using Tecan 2000 inﬁnite pro system,
Austria, Germany. Transfection efﬁciency was normalized using β-
galactosidase activity. All the experiments were done in triplicates
and repeated at least three times.
Western blot
Western blotting was done by infecting the cells at MOI 10 for
12, 24 and 36 h. Mock-infected and JEV-infected cells (1106)
were harvested and washed twice with PBS, and lysed in 90 μl
lysis buffer (50 mM Tris–HCl, 1% NP-40, 0.25% Sodium Deoxycho-
late, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Aprotinin,
1 mM Leupeptin, 1 mM NaF) and incubated at 4 1C for 30 min.
The suspension was spun at 16,000g for 15 min. The supernatants
were aliquoted and stored at 70 1C. Protein was estimated using
Bradford reagent (Sigma-Aldrich, India) and 35 μg of protein was
electrophoresed on 12% SDS-PAGE gels and blotted onto Millipore
Immobilon-P PVDF membranes. Blocking was done for 2 h with
2.5% skimmed milk in PBS containing 0.2% tween-20. Membranes
were washed with PBS containing 0.2% tween-20 after incubating
overnight with optimal titers of primary rabbit anti HLA-F anti-
body. After incubating with secondary HRP conjugated secondary
antibody for 2 h, the blot was developed using Immobilon western
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chemiluminescent HRP substrate (Millipore, India) and visualized
using a Luminescent Image Analyzer (LAS 3000, Fuji Film, Japan).
Flow cytometry
Viable cells (0.5106) were harvested using cell scrapers, stained
and analyzed (Abraham et al., 2010) using a BD Canto II ﬂow
analyzer or FACSCalibur cytometer (Becton Dickinson, USA). Care
was taken to avoid trypsinization to avoid possible cleavage of cell
surface HLA-F during the harvesting procedure. Data was analyzed
usingWinMDI software (Version 2.8). Cell surface expression of total
HLA class I was analyzed using the FITC conjugated mouse anti pan
HLA class I-speciﬁc primary antibody, W6/32 and the appropriate
FITC conjugated isotype antibody. Mouse anti HLA-F monoclonal
antibody, 3D11 and Alexa ﬂuor 488 conjugated goat anti rabbit IgG
antibody were used as primary and secondary antibodies respec-
tively to stain cell surface HLA-F. Control and virus infected cells
were stained at different times p.i., and the data is representative of
three independent experiments.
For Intracellular staining of HB112, 0.5106 cells were ﬁxed with
BD cytoﬁx/cytoperm solution for 20 min at 4 1C. After washing twice
with BD perm wash solution, tubes were incubated with primary
antibody for 1 h at 4 1C. After washing twice with BD perm wash
solution, they were incubated with secondary antibody for 1 h at
4 1C. Finally tubes were washed twice with BD perm wash and cells
were ﬁxed with 4% paraformaldehyde.
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